Results 281 to 290 of about 1,591,450 (336)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2023
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ...
C. Vogel +12 more
semanticscholar +1 more source
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ...
C. Vogel +12 more
semanticscholar +1 more source
Surgical Clinics of North America, 1999
The unfortunate reality of metastatic breast cancer is that all treatment is palliative in nature. This is a disease that currently has no cure and for which therapy is directed towards accentuating survival and relieving symptoms. Current technology allows the prediction and detection of metastases earlier and with greater accuracy. These achievements
C H, Cha, G D, Kennedy, J E, Niederhuber
openaire +2 more sources
The unfortunate reality of metastatic breast cancer is that all treatment is palliative in nature. This is a disease that currently has no cure and for which therapy is directed towards accentuating survival and relieving symptoms. Current technology allows the prediction and detection of metastases earlier and with greater accuracy. These achievements
C H, Cha, G D, Kennedy, J E, Niederhuber
openaire +2 more sources
Oncology Times, 2012
The role of radiotherapy (RT) for metastatic breast cancer is broken down into three settings: the first and most common is palliative radiotherapy, the second is stereotactic RT for oligometastases instead of surgery, and the third is the irradiation of the breast for locoregional control.
Alanyalı S.D., Ozsaran Z.
openaire +3 more sources
The role of radiotherapy (RT) for metastatic breast cancer is broken down into three settings: the first and most common is palliative radiotherapy, the second is stereotactic RT for oligometastases instead of surgery, and the third is the irradiation of the breast for locoregional control.
Alanyalı S.D., Ozsaran Z.
openaire +3 more sources
The Lancet, 2020
BACKGROUND Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer.
J. Cortés +226 more
semanticscholar +1 more source
BACKGROUND Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer.
J. Cortés +226 more
semanticscholar +1 more source
Clinical Orthopaedics and Related Research, 2003
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +4 more sources
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +4 more sources
Oncology Times, 2006
This fourteenth article in our series on breast disease gives an overview of what to look for in the patient with a past history of early breast cancer and how to assess and support the patient with metastatic breast cancer in the general practice setting.
Amanda, Stevanovic +2 more
+5 more sources
This fourteenth article in our series on breast disease gives an overview of what to look for in the patient with a past history of early breast cancer and how to assess and support the patient with metastatic breast cancer in the general practice setting.
Amanda, Stevanovic +2 more
+5 more sources
Current Opinion in ONCOLOGY, 1993
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources